This site uses cookies. By continuing to browse the site without disabling them, you consent to our use of cookies. To learn more about the types of cookies we use, please view our cookie policy.
Continue using the site
Product Query or Adverse Event
Diseases of Addiction
A Worldwide Crisis
Environment, Climate Change and Health and Safety
Patient Safety and Product Quality
Corporate Integrity Agreement
Integrity & Compliance
Advocacy and Stakeholder Engagement
RNS Filings
RNS Filings (Inside Information)
Corporate Alert Service
Webcasts / Audiocasts / Presentations
Buprenorphine Market Modeling Methodology
Share Price Center
Share Price Table
Historic Share Price
Demerger: Base Cost
UK Corporate Governance Code
Statements made under s430(2B) of the Companies Act 2006
Risk Management and Internal Control
Indivior Integrity & Compliance Program
Global Conduct Policies
Managing Your Shareholding
American Depositary Receipts
A. Thomas McLellan Ph. D
Tom has been a career researcher for 40 years with the Treatment Research Institute (which he co-founded in 1992) and the University of Pennsylvania. During his career, Tom has published over 550 articles and chapters on addiction research. He has received several awards including Life Achievement Awards from the American, Swedish, Italian, Egyptian and British Societies of Addiction Medicine and from the American Public Health Association.
From 2009 through 2011, Tom was the Deputy Director of the White House Office of National Drug Control Policy, where he was one of the principal authors of the President's National Drug Control Strategy.
Tom holds a B.A. from Colgate University and an M.S. and Ph.D. from Bryn Mawr College. He received postgraduate training in psychology at Oxford University in England.
Member of the Nomination & Governance Committee
Member of the Science & Policy Committee
MODERN SLAVERY STATEMENT (PDF)
Privacy Policy and Notice for California Residents
© 2020 Indivior PLC | INDIVIOR is a registered trademark of Indivior UK Limited.
You are now leaving Indivior.com to visit Suboxone.com a US product site intended for US residents and healthcare professionals.
Continue Return
You are now leaving Indivior.com.
You are about to leave the Indivior website
The product specific Internet site that you have requested is intended for US audiences, as noted on that site. As a result, the site may contain information on pharmaceuticals that are not approved in other countries or regions.
Do you wish to continue to this product-specific site?
I agree NO